The healthcare sector has gained 46.9 percent over the past six months, outpacing the S&P 500 by 25.5 percentage points on elevated demand for drug development and digital health innovation. But sector breadth masks fundamental deterioration in three names: BioMarin Pharmaceutical, STERIS, and Agilent Technologies. Each exhibits operational strain that does not warrant current valuations.
BioMarin Pharmaceutical (NASDAQ:BMRN) is the most concerning. Adjusted operating margin fell 5.5 percentage points over two years as day-to-day expenses outpaced revenue growth. Return on invested capital lags peers, signaling management's inability to deploy capital. More troubling: the company carries net debt of 6x EBITDA, creating refinancing and dilution risk if operations weaken further. At $59.80 per share, the stock trades at 10.1x forward P/E—cheap only if you believe margin pressure reverses. We do not. Downside target: $48.
STERIS (NYSE:STE) faces a different but equally stubborn problem: no leverage. Annual revenue growth of 7.4 percent over two years lags healthcare benchmarks. Its adjusted operating margin has flatlined over five years, evidence that the company is failing to extract margin expansion from its fixed-cost base. ROIC of 5.7 percent is unacceptable for a capital-intensive business. At $204.34 per share and 18.2x forward P/E, the market is paying full price for a company that has not improved operating efficiency in half a decade. Fair value: $175.
Agilent Technologies (NYSE:A) is the growth laggard. Five-year organic revenue growth of 3.7 percent trails peers materially. Over the past two years, organic sales momentum has deteriorated further, suggesting market share loss to faster-moving competitors. Declining returns on capital confirm that competitive pressure is eroding profitability. At $171.50 per share and 26.3x forward P/E, Agilent trades at a substantial premium to peers despite inferior growth and shrinking returns. This valuation assumes an acquisition or strategic turnaround that management has not demonstrated the capability to execute. Downside target: $145.
Sotera Health (NASDAQGS:SHC), Zimmer Biomet (NYSE:ZBH), Bristol-Myers Squibb (NYSE:BMY), and Illumina (NASDAQ:ILMN) exhibit similar weaknesses: Sotera's 5.3 percent revenue growth trails sector standards. Zimmer Biomet's 5.6 percent growth is muted, and ROIC deterioration signals capital misallocation. BMY faces profit headwinds despite higher revenues. Illumina's organic growth has underperformed benchmarks.
The thesis is straightforward: sector momentum is real, but it benefits companies with pricing power, margin expansion, and capital discipline. BioMarin, STERIS, and Agilent lack these attributes. Their valuations—especially Agilent at 26.3x forward P/E—do not compensate for the risk of further margin pressure, leverage stress, or competitive loss. Within the healthcare rally, we are short these three names.
